Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes
-
Published:2015-04-01
Issue:5
Volume:6
Page:513-517
-
ISSN:1948-5875
-
Container-title:ACS Medicinal Chemistry Letters
-
language:en
-
Short-container-title:ACS Med. Chem. Lett.
Author:
Shah Shrenik K., He Shuwen, Guo Liangqin, Truong Quang, Qi Hongbo, Du Wu, Lai Zhong, Liu Jian, Jian Tianying, Hong Qingmei, Dobbelaar Peter, Ye Zhixiong, Sherer Edward, Feng Zhe, Yu Yang, Wong Frederick, Samuel Koppara, Madiera Maria, Karanam Bindhu V., Reddy Vijay B., Mitelman Stan, Tong Sharon X., Chicchi Gary G., Tsao Kwei-Lan, Trusca Dorina, Feng Yue, Wu Margaret, Shao Qing, Trujillo Maria E., Eiermann George J., Li Cai, Pachanski Michele, Fernandez Guillermo1, Nelson Donald1, Bunting Patricia1, Morissette Pierre1, Volksdorf Sylvia1, Kerr Janet1, Zhang Bei B., Howard Andrew D., Zhou Yun-Ping, Pasternak Alexander, Nargund Ravi P., Hagmann William K.
Affiliation:
1. Department
of Safety Assessment, Merck Research Laboratories, 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
Publisher
American Chemical Society (ACS)
Subject
Organic Chemistry,Drug Discovery,Biochemistry
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|